Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2008 Apr;41(7):635-42.
doi: 10.1038/sj.bmt.1705952. Epub 2007 Dec 17.

Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research

M R Bishop  1 , B R Logan, S Gandham, B J Bolwell, J-Y Cahn, H M Lazarus, M R Litzow, D I Marks, P H Wiernik, P L McCarthy, J A Russell, C B Miller, J Sierra, G Milone, A Keating, F R Loberiza Jr, S Giralt, M M Horowitz, D J Weisdorf
Affiliations
Comparative Study

Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research

M R Bishop et al. Bone Marrow Transplant. 2008 Apr.

Abstract

For adults with high-risk or recurrent ALL who lack a suitable sibling donor, the decision between autologous (Auto) and unrelated donor (URD) hematopoietic stem cell transplantation (HSCT) is difficult due to variable risks of relapse and treatment-related mortality (TRM). We analysed data from two transplant registries to determine outcomes between Auto and URD HSCT for 260 adult ALL patients in first (CR1) or second (CR2) CR. All patients received a myeloablative conditioning regimen. The median follow-up was 77 (range 12-170) months. TRM at 1 year post transplant was significantly higher with URD HSCT; however, there were minimal differences in TRM according to disease status. Relapse was higher with Auto HSCT and was increased in patients transplanted in CR2. Five-year leukemia-free (37 vs 39%) and overall survival (OS) rates (38 vs 39%) were similar for Auto HSCT vs URD HSCT in CR1. There were trends favoring URD HSCT in CR2. The long-term follow-up in this analysis demonstrated that either Auto or URD HSCT could result in long-term leukaemia-free survival and OS for adult ALL patients. The optimal time (CR1 vs CR2) and technique to perform HSCT remains an important clinical question for adult ALL patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative Incidence of Treatment-related Mortality (TRM)
Figure 2
Figure 2
Cumulative Incidence of Relapse
Figure 3
Figure 3
Kaplan-Meier Curves of Leukemia-free and Overall Survival A. Leukemia-free Survival (LFS) B. Overall Survival (OS)
Figure 4
Figure 4
Probability of Overall Survivor (OS) by Donor and Remission Status
See this image and copyright information in PMC

References

    1. Jabbour EJ, Faderl S, Kantarjian HM. Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2005;80:1517–1527. - PubMed
    1. Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, et al. ECOG; MRC/NCRI Adult Leukemia Working Party: Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106:3760–3767. - PubMed
    1. Larson RA. Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. Hematol Oncol Clin North Am. 2000;14:1367–1379. - PubMed
    1. Chao NJ, Forman SJ, Schmidt GM, Snyder DS, Amylon MD, Konrad PN, et al. Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission. Blood. 1991;78:1923–1927. - PubMed
    1. Oh H, Gale RP, Zhang MJ, Ino T, Murakami H, Ohno R, et al. Chemotherapy vs HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission. Bone Marrow Transplant. 1998;22:253–257. - PubMed

Publication types